logo
Plus   Neg
Share
Email

Pre-market Movers For Apr 2 (AVP, THRX, KERX, AEZS, AVII, GRPN, SINA, ESRX, MHS)

Gainers:

Avon Products, Inc. (AVP) is gaining 19 percent to $23.08. Coty Inc. has submitted a non-binding proposal to acquire the company for $23.25 per share in cash. In response, Avon rejected Coty's offer.

Decliners:

Keryx Biopharmaceuticals Inc. (KERX) is plunging 59 percent to $2.04. AEterna Zentaris Inc. (AEZS) is plunging 55 percent to $0.95. The companies announced that the Phase 3 X-PECT clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo. The trial involving 468 patients in 65 sites in the U.S was conducted by AEterna Zentaris' North American licensee partner, Keryx.

AVI BioPharma, Inc. (AVII) is falling 34 percent to $1.02. The company announed that treatment with its eteplirsen met the primary efficacy endpoint in a randomized, double-blind, placebo-controlled Phase IIb study in boys with Duchenne muscular dystrophy.

Groupon, Inc. (GRPN) is falling 11 percent to $16.31. The company announced a revision to its reported results for its fourth quarter and year ended December 31, 2011, primarily related to an increase to its refund reserve accrual to reflect a shift in fourth quarter deal mix and higher price point offers, which have higher refund rates.

SINA Corp. (SINA) is falling 6 percent to $61.00 amidst the news that China has launched censorship move in an effort to beat back the rumors following the ouster of Bo Xilai.

Trading halt:

Trading in shares of Express Scripts (ESRX) and Medco Health Solutions (MHS) were halted. Express Scripts completed its previously announced $29.1 billion acquisition of Medco today.

Trading in shares of ChinaCast Education Corp. (CAST) was halted. Ron Chan, ex Chairman and CEO of the company has resigned from the board. Ron Chan attributed his decision to serious disagreements he had with the group of directors who recently has come to control the board and the company. Additionally, the company said it received NASDAQ notification letter regarding delayed Form 10-K filing.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
An administrative law judge has ruled that Minnesota regulators should approve Enbridge Inc.'s proposal to replace its aging Line 3 crude oil pipeline only if the company follows the existing route and not its preferred route. Enbridge has applied to replace its Line 3 pipeline from Alberta with new pipe along its existing route. In Minnesota, the planned route deviates from the existing route. CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV... Most Americans have access to health care, though costs and services vary from state to state. However, higher costs do not necessarily translate into better results. The U.S. continues to be outperformed by other wealthy nations on several measures like life expectancy, disease burden and health...
Follow RTT